Introduction to Personalized Therapeutics and Pharmacogenomics

How this online course works:

ORGANIZATION: 
The course is divided into four lecture modules with suggested supplemental learning materials.

TECH REQUIREMENTS:
For this course, you need access to a current Mac or PC and an up-to-date browser (Chrome, Firefox, Safari, or Internet Explorer).

N-Lighten Program Goals

The N-Lighten Program has mapped its workforce development goals to the Core Competencies for Clinical and Translational Research and the ECRPTQ/JTF Harmonized Core Competencies for Clinical Research Professionals.s to an external site.

The parent course for this offering (BIOPHARM 5700) is one of the many graduate courses offered in the OSU Masters of Applied Clinical and Preclinical Research.  To learn more please watch our program introductory video (click here) and visit the MACPR website at macpr.osu.edu

Course Description

BIOPHARM 5700: Introduction to Personalized Therapeutics and Pharmacogenomics (Dr. Wolfgang Sadee)

• Exploration of the trend to therapy tailored to the individual patient rather than “one drug fits all;” inter-individual differences in drug responses, with emphasis on genetic and genomic factors; ethical, regulatory and economic issues that impact drug therapies.

Targeted Learners

• T/K Scholars
• Clinical research coordinators
• Research Team Members
• Clinicians

Objectives

The objectives associated with this educational offering are the following:

• Discuss factors determining wellness and risk of disease, and those contributing to variability in drug response and adverse drug reactions
• Identify genetic and genomic elements and main scientific disciplines critical to pharmacogenomics
• Assess promising avenues for improving health care and therapy and evaluate the potential of pharmacogenomics in improving healthcare and therapy for individual patient survey implementation efforts in the clinic and at the FDA

Syllabus:

Topic 1- Factors determining wellness and risk of disease

Topic 2- Genetics and Genomic and Pharmacogenomic Concepts

Topic 3- Implementation in the Clinic to Optimize Therapy

Topic 4- Defining Personalized Therapeutics

Instructor:

Wolfgang Sadee, Dr.rer.nat

Wolfgang Sadee, Dr.rer.nat. 
Felts Mercer Professor of Medicine and Pharmacology
Department of Internal Medicine, Division of Human Genetics
Chair, Department of Pharmacology 
Joint appointment in the Division of Human Genetics, Department of Internal Medicine

Phone: (614) 292-1597
Fax: (614) 292-7232
wolfgang.sadee@osumc.edu

Research Interests 
Pharmacogenetics-Pharmacogenomics of drug receptors and transporters, Genetics of drug addiction, other CNS disorders, cardiovascular diseases, and cancer. Chemogenomics and anticancer drug discovery.

Pharmacogenetics-Pharmacogenomics
Research conducted in the OSU Program in Pharmacogenomics aims at finding biomarkers that guide effective treatment of individual patients. We assume that genetic differences among individuals play a significant role in determining treatment outcomes. In the emerging era of personalized medicine, use of genetic information has vast promise in reducing toxicity and improving efficacy of drug therapy. This applies to drugs already in routine use and to novel drugs emerging from the discovery pipeline. While the potential of pharmacogenomics is great, translation into clinical practice has been slow.

Main hurdles in rapid implementation include the complexity of human genetics - we often do not know the impact of a gene variant on disease or therapy outcome in patients. The Sadee laboratory has developed a novel approach to finding genetic variations in key genes already know to play a significant role - either as drug targets or as disease risk factors. We have applied this approach to >60 candidate genes implicated in CNs disorders, cancer, cardiovascular disease, and inflammation and autoimmune disorders, including multiple sclerosis, and in drug metabolism. This has led to discoveries of genetic variants in key genes affecting biogenic amine activity - such as serotonin and dopamine, involved in depression, psychosis, cognition and memory, autism, neurodegenerative disorders, and drug addiction. These discoveries are all the more surprising as some of these key genes had already been under intense study elsewhere.

We have already taken these newly discovered genetic markers into clinical trials, finding unexpectedly strong association in some cases, and raising the hope for the development of viable biomarkers. We are currently initiating a series of clinical collabortions, addressing the following medical needs and searching for potential biomarkers/drug targets: cancer (e.g., colon, lung, breast), hypertension and myocardial infarction, CNS disorders, including drug addiction, and HIV/AIDS.

Education
M.Pharmacy, Freie Universitat Berlin, Pharmacy, 1966
Dr.rer.nat., Freie Universitat Berlin, Pharmaceutical Chemistry, 1968

More About Dr. Sadee